MedTrace Logo

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

NCT03777930 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-12-19

No results posted yet for this study

Summary

To observe the effect of thalidomide combined with megestrol acetate on lymphocyte, inflammatory factor regulation and nutritional status in patients with advanced malignant tumors.

Conditions

  • Cancer, Therapy-Related

Interventions

DRUG

Chemotherapy drugs

According to the NCCN Guidelines

DRUG

thalidomide and megestrol acetate

The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks

OTHER

optimal support treatment

Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks

DRUG

thalidomide and megestrol acetate

The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks

Sponsors & Collaborators

  • Shenzhen Fifth People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-10
Primary Completion
2020-10-10
Completion
2021-06-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777930 on ClinicalTrials.gov